BetterLife Pharma (STU:NPAU) LT-Debt-to-Total-Asset : 2.83 (As of Jan. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BetterLife Pharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BetterLife Pharma's long-term debt to total assests ratio for the quarter that ended in Jan. 2024 was 2.83.

BetterLife Pharma's long-term debt to total assets ratio declined from Jan. 2023 (5.85) to Jan. 2024 (2.83). It may suggest that BetterLife Pharma is progressively becoming less dependent on debt to grow their business.

BetterLife Pharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for BetterLife Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma LT-Debt-to-Total-Asset Chart

BetterLife Pharma Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.56

0.78

5.85

2.83

BetterLife Pharma Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															5.85	0.45	0.49	1.08	2.83

BetterLife Pharma LT-Debt-to-Total-Asset Calculation

BetterLife Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jan. 2024 is calculated as

LT Debt to Total Assets (A: Jan. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Jan. 2024 )	/	Total Assets (A: Jan. 2024 )
	=	0.629	/	0.222
	=

BetterLife Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2024 is calculated as

LT Debt to Total Assets (Q: Jan. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jan. 2024 )	/	Total Assets (Q: Jan. 2024 )
	=	0.629	/	0.222
	=

BetterLife Pharma (STU:NPAU) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BetterLife Pharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BetterLife Pharma (STU:NPAU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (STU:NPAU) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

BETRF:USA NPAU:Germany BETR:Canada

Address

1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6

Website

https://www.abetterlifepharma.com

BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.

BetterLife Pharma (STU:NPAU) Headlines

No Headlines